Chronic myeloid leukemiaNews & Research
13 curated articles for Chronic myeloid leukemia — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Future medicinal chemistry Apr 21, 2026
Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways.
Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy characterized by the presence of the Philadelphia chromosome, which generates the constitutively active BCR::ABL1 tyrosine kinase, driving uncontrolled myeloid proliferation. Although BCR::ABL1-targeted tyrosine kinase inhibitors (T...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Journal of physiology and biochemistry Apr 20, 2026
Roles of extracellular vesicles in the pathogenesis of chronic myeloid leukemia.
Extracellular vesicles (EVs) are lipid bilayer-enclosed particles released by cells into the extracellular space. They are produced by the majority of cell types under both physiological and pathological conditions. EVs mediate intercellular communication by delivering bioactive molecules - such as ...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- International journal of hematology Apr 15, 2026
Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.
The European LeukemiaNet recommendations for the management of chronic myeloid leukemia (CML) consider achievement of major molecular response (MMR) within 12 months to be an optimal response (OR). However, no currently available tool can predict treatment response at diagnosis. This study aime...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Biology Apr 13, 2026
An AI-Enabled Single-Cell Transcriptomic Analysis Pipeline for Gene Signature Discovery in Natural Killer Cells Linked to Remission Outcomes in Chronic Myeloid Leukemia.
A major technical challenge in single-cell transcriptomics is the absence of an integrative analytic pipeline that can simultaneously leverage gene regulatory network (GRN) architecture, AI-assisted gene panel discovery, and functional relevance analyses to generate coherent biological insights. Exi...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Expert review of hematology Apr 6, 2026
Evolution of the European LeukemiaNet recommendations for chronic myeloid leukemia.
Chronic myeloid leukemia (CML) management has been revolutionized by tyrosine kinase inhibitors (TKIs), leading to near-normal life expectancy for most patients diagnosed in the chronic phase. The European LeukemiaNet (ELN) recommendations provide the internationally recognized framework for the dia...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Cancers Mar 28, 2026
Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities.
Background : Mitochondria are multifunctional organelles that play a central role in maintaining cellular homeostasis by regulating energy metabolism, reactive oxygen species (ROS) generation, ion homeostasis, and apoptotic signaling. Dynamic processes such as mitochondrial fission, fusion, and intr...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Blood Mar 26, 2026
Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.
Many patients receiving frontline tyrosine kinase inhibitors (TKIs) for chronic-phase chronic myeloid leukemia (CML-CP) experience inadequate disease control and/or adverse events (AEs) that impair quality of life. Treatments offering optimal efficacy, safety, and tolerability will support long-term...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Biomedical journal Mar 14, 2026
From inhibition to regulation: serpins in health and disease.
This issue of the Biomedical Journal highlights regulatory mechanisms that shape aging, disease progression, and biological complexity across molecular, cellular, and systems levels. A central theme is plasminogen activator inhibitor-1 (PAI-1) as a multifunctional regulator linking fibrinolysis, cel...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Bioorganic chemistry Mar 9, 2026
Bioactive treatments against chronic myeloid leukemia from Hypericum lancasteri targeting p53 pathway.
The discovery of biologically active compounds from plants is an emerging challenge in natural pharmaceutical development. Here, we report the comprehensive strategy for undescribed compounds discovery targeting p53 pathway from Hypericum lancasteri against chronic myeloid leukemia (CML). The UHPLC-...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Expert review of hematology Mar 6, 2026
Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia.
Chronic myeloid leukemia (CML) has been transformed by ATP-competitive BCR:ABL1 tyrosine kinase inhibitors (TKIs); however, resistance, intolerance, and long-term toxicity remain clinically relevant challenges, particularly in patients requiring prolonged therapy or multiple treatment lines. Ascimin...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Leukemia Feb 5, 2026
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
Treatment-free remission (TFR) after discontinuation of ABL tyrosine kinase inhibitors (TKIs) is an important therapeutic goal in chronic myeloid leukemia (CML). Interferon-α (IFN) has been suggested to promote durable TFR. The phase 3 ENDURE trial (NCT03117816; EUDRA-CT 2016-001030-94) prospe...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Haematologica Feb 2, 2026
Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey.
For patients with chronic myeloid leukemia in chronic phase (CML-CP), disease management, treatment experiences, and decisions around switching therapies due to resistance or intolerance can have significant impacts on their lives. Experiences and perspectives regarding the roles of patients and tre...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
- Cell reports Jan 30, 2026
Intestinal low-abundant bacteria drive MyD88/Trif-dependent CD8 + T cell exhaustion in chronic myeloid leukemia.
Leukemia stem cells (LSCs) resist therapy and immune elimination, but the basis of their escape from cytotoxic T cell (CTL) attack is unclear. Here, we show that specific low-abundance gut commensals of the genera Sutterella and Bilophila suppress anti-leukemic immunity in chronic myeloid leukemia (...
Why it matters: Recent peer-reviewed research on Chronic myeloid leukemia that may be relevant for patients and caregivers.
More on Chronic myeloid leukemia
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.